Correction to Revenio Group Corporation’s Stock Exchange Release published on June 5, 2020 at 13.30: Notice pursuant to chapter 9, section 5 of the securities market act

Revenio Group Corporation, Stock Exchange Release, June 5, 2020 at 15.15

Correction to Revenio Group Corporation’s Stock Exchange Release published on June 5, 2020 at 13.30: Notice pursuant to chapter 9, section 5 of the securities market act

Revenio Group Corporation has June 5, 2020 received a notification of change in holdings in accordance with Chapter 9, Section 5 of the Securities Markets Act that William Demant Invest A/S’s share of the total number of shares and voting rights in Revenio Group Corporation has increased to more than ten per cent.

William Demant Invest A/S now holds 2,705,336 shares in Revenio Group Corporation, instead of the previously announced 26,599,021, which is 10.16 per cent of the company's shares and voting rights.

Total of 20,490 new share subscriptions based on the company's 2015B stock options and total of 7,725 new share subscriptions based on the company’s 2015C stock options entered into the trade register today. The total number of Revenio Group Corporation's shares recorded in the trade register is now 26.627.236. Consequently, William Demant Invest A/S holds 10.16% of the company's shares and voting rights, instead of the previously announced 10.17%.

Revenio Group Corporation

Board of Directors

For further information, please contact:
Robin Pulkkinen, CFO, tel.  +358 50 505 9932
robin.pulkkinen@revenio.fi
www.revenio.fi

DISTRIBUTION:

Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media

www.revenio.fi 

Revenio Group in brief

Revenio, a health technology group operating in the international markets, is one of the global leaders in ophthalmic appliances.

The Revenio Group consists of Revenio Group Oyj, Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.

The common denominators of Revenio's business operations include patient-oriented screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The aim is to improve the quality of life through health technology solutions which enable more effective diagnostics. Revenio Group’s focus is on the early detection of glaucoma, diabetic retinopathy and macular degeneration, and the monitoring of these during the treatment process. Revenio Research concentrates on the commercialization of systems supporting the diagnosis of and treatment planning for skin cancer and asthma.

In 2019, Revenio Group's net sales totalled EUR 49.5 million, with its net operating profit standing at 25.5%. Revenio Group Corporation is listed on Nasdaq Helsinki.


Subscribe